SIRPA and B-cell non-Hodgkin lymphoma: We previously showed that an antibody to SIRPα that blocks its interaction with CD47 markedly enhanced the inhibitory effect of rituximab, an antibody to human (h) CD20, on the growth of human B cell lymphoma in immunodeficient mice (13, 14).